182 related articles for article (PubMed ID: 26503262)
1. Trends in Receipt and Timing of Multimodality Therapy in Early-Stage Pancreatic Cancer.
Dimou F; Sineshaw H; Parmar AD; Tamirisa NP; Jemal A; Riall TS
J Gastrointest Surg; 2016 Jan; 20(1):93-103; discussion 103. PubMed ID: 26503262
[TBL] [Abstract][Full Text] [Related]
2. Trajectory of care and use of multimodality therapy in older patients with pancreatic adenocarcinoma.
Parmar AD; Vargas GM; Tamirisa NP; Sheffield KM; Riall TS
Surgery; 2014 Aug; 156(2):280-9. PubMed ID: 24851723
[TBL] [Abstract][Full Text] [Related]
3. Regional variation in the treatment of pancreatic adenocarcinoma: Decreasing disparities with multimodality therapy.
Kasumova GG; Eskander MF; de Geus SWL; Neto MM; Tabatabaie O; Ng SC; Miksad RA; Mahadevan A; Rodrigue JR; Tseng JF
Surgery; 2017 Aug; 162(2):275-284. PubMed ID: 28487044
[TBL] [Abstract][Full Text] [Related]
4. Trends in the treatment of resectable pancreatic adenocarcinoma.
Raigani S; Ammori J; Kim J; Hardacre JM
J Gastrointest Surg; 2014 Jan; 18(1):113-23. PubMed ID: 24002769
[TBL] [Abstract][Full Text] [Related]
5. Differences in receipt of multimodality therapy by race, insurance status, and socioeconomic disadvantage in patients with resected pancreatic cancer.
Hao S; Mitsakos A; Irish W; Tuttle-Newhall JE; Parikh AA; Snyder RA
J Surg Oncol; 2022 Aug; 126(2):302-313. PubMed ID: 35315932
[TBL] [Abstract][Full Text] [Related]
6. Management for Elderly Women With Advanced-Stage, High-Grade Endometrial Cancer.
Rauh-Hain JA; Pepin KJ; Meyer LA; Clemmer JT; Lu KH; Rice LW; Uppal S; Schorge JO; Del Carmen MG
Obstet Gynecol; 2015 Dec; 126(6):1198-1206. PubMed ID: 26551187
[TBL] [Abstract][Full Text] [Related]
7. Multimodality therapy for pancreatic cancer in the U.S. : utilization, outcomes, and the effect of hospital volume.
Bilimoria KY; Bentrem DJ; Ko CY; Tomlinson JS; Stewart AK; Winchester DP; Talamonti MS
Cancer; 2007 Sep; 110(6):1227-34. PubMed ID: 17654662
[TBL] [Abstract][Full Text] [Related]
8. Trends in the use of evidence-based therapy for resectable gastric cancer.
Snyder RA; Penson DF; Ni S; Koyama T; Merchant NB
J Surg Oncol; 2014 Sep; 110(3):285-90. PubMed ID: 24891231
[TBL] [Abstract][Full Text] [Related]
9. Trends in the use of pre-operative radiation for adenocarcinoma of the pancreas in the United States.
Burke EE; Marmor S; Portschy PR; Virnig BA; Cho LC; Tuttle TM; Jensen EH
HPB (Oxford); 2015 Jun; 17(6):542-50. PubMed ID: 25726950
[TBL] [Abstract][Full Text] [Related]
10. Trends in the use and impact of neoadjuvant chemotherapy on perioperative outcomes for resected gastric cancer: Evidence from the American College of Surgeons National Cancer Database.
Greenleaf EK; Hollenbeak CS; Wong J
Surgery; 2016 Apr; 159(4):1099-112. PubMed ID: 26704785
[TBL] [Abstract][Full Text] [Related]
11. Disparities in utilization of treatment for clinical stage I-II pancreatic adenocarcinoma by area socioeconomic status and race/ethnicity.
Swords DS; Mulvihill SJ; Brooke BS; Skarda DE; Firpo MA; Scaife CL
Surgery; 2019 Apr; 165(4):751-759. PubMed ID: 30551868
[TBL] [Abstract][Full Text] [Related]
12. Role of neoadjuvant therapy in the multimodality treatment of older patients with pancreatic cancer.
Cooper AB; Holmes HM; des Bordes JK; Fogelman D; Parker NH; Lee JE; Aloia TA; Vauthey JN; Fleming JB; Katz MH
J Am Coll Surg; 2014 Jul; 219(1):111-20. PubMed ID: 24856952
[TBL] [Abstract][Full Text] [Related]
13. Geographic disparities in surgical treatment recommendation patterns and survival for pancreatic adenocarcinoma.
Salami A; Alvarez NH; Joshi ART
HPB (Oxford); 2017 Nov; 19(11):1008-1015. PubMed ID: 28838634
[TBL] [Abstract][Full Text] [Related]
14. Surgeon-Level Variation in Utilization of Local Staging and Neoadjuvant Therapy for Stage II-III Rectal Adenocarcinoma.
Swords DS; Skarda DE; Sause WT; Gawlick U; Cannon GM; Lewis MA; Scaife CL; Gygi JA; Tae Kim H
J Gastrointest Surg; 2019 Apr; 23(4):659-669. PubMed ID: 30706375
[TBL] [Abstract][Full Text] [Related]
15. Young Adults With Pancreatic Cancer: National Trends in Treatment and Outcomes.
Alese OB; Jiang R; Shaib W; Wu C; Akce M; Gaines T; Ni L; Behera M; El-Rayes BF
Pancreas; 2020 Mar; 49(3):341-354. PubMed ID: 32132513
[TBL] [Abstract][Full Text] [Related]
16. Evaluating the Impact of ESPAC-1 on Shifting the Paradigm of Pancreatic Cancer Treatment.
Winer LK; Cortez AR; Ahmad SA; Wima K; Olowokure O; Latif T; Kharofa J; Patel SH
J Surg Res; 2021 Mar; 259():442-450. PubMed ID: 33059910
[TBL] [Abstract][Full Text] [Related]
17. Palliative therapy for stage IV rectal adenocarcinoma: how frequently is it used?
Kulaylat AS; Rivet EB; Hollenbeak CS; Stewart DB
J Surg Res; 2017 Oct; 218():1-8. PubMed ID: 28985835
[TBL] [Abstract][Full Text] [Related]
18. Utilization and impact of adjuvant chemotherapy among patients with resected stage II colon cancer: a multi-institutional analysis.
Ejaz A; Casadaban L; Maker AV
J Surg Res; 2017 Jul; 215():12-20. PubMed ID: 28688636
[TBL] [Abstract][Full Text] [Related]
19. Overall survival is increased among stage III pancreatic adenocarcinoma patients receiving neoadjuvant chemotherapy compared to surgery first and adjuvant chemotherapy: An intention to treat analysis of the National Cancer Database.
Shubert CR; Bergquist JR; Groeschl RT; Habermann EB; Wilson PM; Truty MJ; Smoot RL; Kendrick ML; Nagorney DM; Farnell MB
Surgery; 2016 Oct; 160(4):1080-1096. PubMed ID: 27522556
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant
Hashmi A; Kozick Z; Fluck M; Hunsinger MA; Wild J; Arora TK; Shabahang MM; Blansfield JA
Am Surg; 2018 Sep; 84(9):1439-1445. PubMed ID: 30268172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
